DAMORA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
DAMORA THERAPEUTICS, INC. (DMRA) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price of $21.57 per share as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice · last filed 2026-08-10
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $21.57.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $25.33.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $30.45.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $106.73.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $21.57 10-Q · filed 2026-08-10 |
| 2026-03-31 | $25.33 10-Q · filed 2026-05-12 |
| 2025-12-31 | $30.45 10-K · filed 2026-03-19 |
| 2025-09-30 | $106.73 10-Q · filed 2025-11-06 |
| 2025-06-30 | $112.44 10-Q · filed 2025-08-05 |
| 2025-03-31 | $119.46 10-Q · filed 2025-05-08 |
| 2024-12-31 | $129.02 10-K · filed 2025-03-19 |
| 2024-09-30 | $126.10 10-Q · filed 2024-11-01 |
| 2024-06-30 | $5.05 10-Q · filed 2024-08-12 |
| 2024-03-31 | $5.07 10-Q · filed 2024-04-29 |
| 2023-12-31 | $5.31 10-K · filed 2024-03-08 |
| 2023-09-30 | $5.31 10-Q · filed 2023-11-06 |
| 2023-06-30 | $5.39 10-Q · filed 2023-07-31 |
| 2023-03-31 | $5.36 10-Q · filed 2023-04-28 |
| 2022-12-31 | $5.65 10-K · filed 2023-03-09 |
| 2022-09-30 | $5.52 10-Q · filed 2022-11-08 |
| 2022-06-30 | $5.49 10-Q · filed 2022-07-29 |
| 2022-03-31 | $5.36 10-Q · filed 2022-04-29 |
| 2021-12-31 | $4.13 10-K · filed 2022-02-17 |
| 2021-09-30 | $6.67 10-Q · filed 2021-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |